Vaccines help prevent us getting sick with COVID-19, but treatments help us get better if we do. To that end, a number of doctors and patients are at the forefront of global efforts to develop those treatments.

This article looks at a number of existing drugs approved for specific diseases and conditions that are in clinical trials for use as a COVID-19 therapeutic.

The DSMB is a committee of clinical research experts, including physicians, statisticians, and patient advocates, who are monitoring the progress of the Company’s clinical trial, and are reviewing safety and effectiveness data while the trial is ongoing.

In the January 5th edition of the European Archives of Psychiatry and Clinical Neuroscience, the authors of an independent research review identified Ifenprodil as a possible repurposed drug candidate for the treatment of COVID-19, Vancouver-based Algernon told shareholders. 

“The study is an adaptive pilot to pivotal trial design based on guidance documents from the World Health Organization (WHO) to determine if Ifenprodil can improve clinical symptoms of COVID-19 by reducing the number of COVID-19 diagnosed patients from progressing to mechanical ventilation with intubation and death,” said Dr. Mark Williams, Algernon’s CSO.

Moreau shares with Proactive how this study will be conducted and where they are as far as Health Canada is concerned.

The study will be an adaptive pilot to pivotal trial design based on guidance documents from the World Health Organization (WHO) to determine if Ifenprodil can improve clinical symptoms and reduce the number of COVID-19 infected patients from progressing to mechanical ventilation with intubation and death.

Related news:

Ethics submission is the next step in the company’s clinical development program of its re-purposed drug Ifenprodil for IPFand chronic cough. The company has also recently started to expand its investigation of Ifenprodil for acute lung injury (ALI) and COVID-19.